Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
74.13
+0.68 (0.93%)
Aug 14, 2026, 4:00 PM EDT - Market closed

Cytokinetics Stock Forecast

Stock Price Forecast

According to 22 analysts polled by S&P Global, Cytokinetics stock has a consensus rating of "Buy" and an average price target of $109.9. The average 1-year stock price forecast is 48.25% higher than the current stock price, while the lowest is $85 (+14.66%) and the highest is $146 (+96.95%).

Price Target: $109.9 (+48.25%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$85$109.9$107.5$146
Change+14.66%+48.25%+45.02%+96.95%

Analyst Ratings

The average analyst rating for Cytokinetics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy101112131313
Buy777777
Hold333222
Sell000000
Strong Sell000000
Total202122222222

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Barclays
Barclays
Buy
Maintains
$95$110
BuyMaintains$95$110+48.39%Aug 14, 2026
Bank of America Securities
Bank of America Securities
Hold
Maintains
$85
HoldMaintains$85+14.66%Aug 14, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$140
BuyReiterates$140+88.86%Aug 13, 2026
J.P. Morgan
J.P. Morgan
Buy
Reiterates
$97$103
BuyReiterates$97$103+38.95%Aug 13, 2026
Truist Financial
Truist Financial
Buy
Maintains
$112
BuyMaintains$112+51.09%Aug 11, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
150.11M
from 88.04M
Increased by 70.50%
Revenue Next Year
422.54M
from 150.11M
Increased by 181.49%
EPS This Year
-5.95
from -6.54
EPS Next Year
-4.44
from -5.95
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
70.43M94.59M7.53M18.47M88.04M150.11M
Revenue Growth
26.15%34.31%-92.04%145.34%376.56%70.50%
Operating Income
-186.31M-324.20M-496.21M-536.25M-612.26M-732.15M
Net Income
-215.31M-388.96M-526.24M-589.53M-784.96M-810.08M
EPS
-----6.54-5.95
Free Cash Flow
-179.83M-127.01M-260.37M-241.29M-379.62M-591.00M
No. Analysts
-----19
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High222.4M
Avg150.1M
Low110.6M

Revenue Growth

Revenue Growth202620272028
High
152.6%
Avg
70.5%
Low
25.6%

EPS Forecast

EPS202620272028
High-4.75
Avg-5.95
Low-6.38

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-